Basic information Anticancer drugs Treatment of advanced (non-small cell lung cancer) NSCLC Preparation method Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Tinib Antineoplastic drugs >  Vandetanib


Basic information Anticancer drugs Treatment of advanced (non-small cell lung cancer) NSCLC Preparation method Safety Related Supplier
Vandetanib Basic information
Vandetanib Chemical Properties
  • Melting point:240-2430C
  • Boiling point:538.2±50.0 °C(Predicted)
  • Density 1.406
  • Flash point:279.3℃
  • storage temp. -20?C Freezer
  • pka8.92±0.10(Predicted)
  • CAS DataBase Reference443913-73-3
Safety Information
  • Safety Statements 24/25
  • HS Code 29333220
Vandetanib Usage And Synthesis
  • Anticancer drugsVandetanib is a kind of small molecule multi-targeted tyrosine kinase inhibitor studied and developed by the British AstraZeneca Company. In April 2011, it was approved the US FDA for entering into market under the trade name Zactima. The drug, as a tablet, can be applied to the treatment of advanced medullary thyroid cancer of adult patients.
    Vandetanib is a multi-targeted tyrosine kinase inhibitor, and belongs to the Anilinoquinazoline compounds, called "second generation Iressa”. It not only acts on the tumor cells, EGFR, VEGFR and RET tyrosine kinases, but can also inhibit other kind of tyrosine kinases and serine/threonine kinases. Vandetanib is the first approved drugs approved for treatment of medullary thyroid carcinoma. It is suitable for treating unresectable, locally advanced or metastatic-symptoms or progressive medullary thyroid carcinoma. A randomized, placebo-controlled clinical trial results have showed that vandetanib can significantly delay the progression time of locally advanced or metastatic medullary thyroid cancer. The recommended daily dose is 300 mg (oral), when the patient exhibits tolerance to drugs or being not able to tolerate the toxicity, they should stop treatment immediately. Those most common adverse reactions of this medicine include diarrhea, rash, acne, nausea, hypertension, headache, fatigue, loss of appetite and abdominal pain. The adverse reactions is dose-related; at <300 mg/d, the patient has a well tolerance with the maximum tolerated dose (MTD) being 300mg. There are many kinds disease types contained in the Ⅱ phase clinical study. The NSCLC clinical trials of vandetanib are currently under way for China.
    British AstraZeneca Company, in May 2001 and October 2001, respectively, had obtained preferential access to the world's patent (WO2001032651, WO 2001074360) and applied corresponding protection on the formula, synthesis methods and pharmaceutical compositions of these compounds (including bonus salt). Vandetanib can inhibit the development of medullary thyroid carcinoma, and is the first FDA-approved drug for the treatment of the disease and will provide support for the treatment of advanced medullary thyroid cancer in adult patients.
    The above information is edited by the chemicalbook of Dai Xiongfeng.
  • Treatment of advanced (non-small cell lung cancer) NSCLCA study published in the [Journal of Clinical Oncology] have showed that compared with gefitinib which only has inhibitory effect on EGFR, vandetanib can effectively extend the progression-free survival period of the non-small cell lung cancer (NSCLC) patients.
    In this phase II clinical trial conducted by doctors Ronald B. Natale from Los Angeles Cedars-Sinai Cancer Center, clinical study compared the treatment efficacy of vandetanib (300 mg/d) and gefitinib (250mg/d) on 168 cases of NSCLC patients who had been subject to failing first-line or second-line chemotherapy. Compared with gefitinib, vandetanib significantly increased efficiency and prolonged the progression-free survival, period respectively, by 8% and 1%, 11.9 weeks and 8.1 weeks, (P = 0.011). In clinical trials, if there is progression of the disease or if the patient can’t tolerate the toxicity, they allowed the patients to change the treatment regimen. Experimental results had shown that using gefitinib for replacing vandetanib in patients gave a disease control rate of 14% while using vandetanib to replace gefitinib gave a disease control rate of 32%. The overall survival period in the case of vandetanib → gefitinib was 6.1 months while it was 7.4 months in the cases of gefitinib → vandetanib.
  • Preparation methodUse 4-hydroxy-3-methoxy-benzoic acid ethyl ester as a starting material, go through substitution, reduction, nitrification, reduction, cyclization aromatization to give 4-chloro-6-methoxy--7-(N-methyl piperidin-4-ylmethoxy) quinazoline (A), A was then reacted with 4-bromo-2-aniline to obtain the targeted compound vandetanib.
  • DescriptionIn April 2011, the U.S. FDA approved vandetanib (ZD6474) for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in adult patients with inoperable advanced ormetastatic disease. Vandetanib inhibits KDR/VEGFR2, VEGFR3, EGFR, and RET kinases with IC50's of 40, 110, 500, and <100 nM, respectively. In athymic mice bearing MTC tumors, a 14.5-fold reduction of tumor volume was observed after 45 days of treatment with vandetanib at 50 mg/kg/day. The decrease in tumor volume was accompanied by decreases in mitotic index (Ki67) and tumor angiogenesis in treated xenografts. Key steps in the synthesis of vandetanib include the displacement of the chlorine atom from 7-benzyloxy-4-chloro-6-methoxyquinazoline with 4-bromo-2- fluoroaniline under acidic conditions in a protic solvent and a Mitsunobu reaction of a N-protected piperidine alcohol with a phenol.
  • Chemical PropertiesYellow Solid
  • OriginatorAstra Zeneca (United Kingdom)
  • UsesVandetanib (Zactima, ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
  • UsesVandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM
  • UsesVandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor kinase activity. The activity of Vandetanib plus Docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC).
  • UsesVandetanib is a broad spectrum, orally available kinase inhibitor that targets primarily tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with IC50 values in the nanomolar range. It also potently blocks non-receptor tyrosine kinases, including ABL, RET, and SRC, as well as several serine/threonine kinases. Primarily because of its effects on receptor tyrosine kinases like VEGFR and EGFR, vandetanib inhibits angiogenesis, cell growth, and metastasis and is effective against certain forms of cancer.[Cayman Chemical]
  • brand nameZactima (AstraZeneca);Caprelsa.
Vandetanib (443913-73-3)Related Product Information
Vandetanib SupplierMore
  • Company Name:Hefei TianRui Pharmaceutical Chemistry Co., Ltd. Gold
  • Tel:13956024211 0551-68933033
  • Company Name:Zhongshan Haihong Medicine Co. Ltd Gold
  • Tel:18824993998 0760-86925768-
  • Company Name:Shanghai Kuanghao Chemistry Technology Co., Ltd. Gold
  • Tel:15900820856 021-37285271
  • Company Name:Hubei Dibai Chemical Co., Ltd. Gold
  • Tel:15872383390 027-87058617-
  • Company Name:Wuhan Chemprospect Pharmaceutical Co., Ltd. Gold
  • Tel:13971349987
Related articles